Andere talen Takeda Pharmaceutical Company Limited BOERSE MUENCHEN

Aandelen

TKD

JP3463000004

Real Time BOERSE MUENCHEN Andere beurzen 08:00:04 25-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
24,51 ^EUR	+1,87%		-2,47%	-7,07%

24/06	Hutchmed China stelt vast dat Takeda EU-goedkeuring heeft gekregen voor Fruzaqla	AN
24/06	Takeda's behandeling tegen orgaantransplantatie-infecties goedgekeurd door Japanse regelgevers	MT

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Hutchmed China notes Takeda obtains EU approval for Fruzaqla	24/06
Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators	24/06
Hutchmed (China), Takeda Secure EU Approval for Colorectal Cancer Treatment	24/06
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies	24/06
Takeda Announces Approval of LIVTENCITY® by the Japanese Ministry of Health, Labour and Welfare	24/06
Japanese Shares End Higher as BoJ Indicates Readiness for Policy Shifts	24/06
Takeda Receives European Commission Approval for Colorectal Cancer Treatment	24/06
Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)	24/06
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia	23/06
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia	23/06
Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla	21/06
Takeda Pharmaceutical Gets European Commission Approval for Cancer Treatment	21/06
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer	21/06
Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer	21/06
Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older	21/06
Les sorcières épouvantent l'IA	21/06
Japanese Stocks End Little Changed After Three-Day Winning Streak on Inflation and Yen Woes	21/06
En Direct des Marchés : LVMH, Accor, Alstom, Atos, Casino, Plastivaloire, Boeing, Geberit...	21/06
Borsa di Italia: Le streghe terrorizzano l'AI	21/06
Bolsa de Madrid: Las brujas aterrorizan a la IA	21/06

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Takeda Pharmaceutical Company Limited BOERSE MUENCHEN

Aandelen

TKD

JP3463000004

Andere talen

Filters